TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE

This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or...

Full description

Saved in:
Bibliographic Details
Main Authors NEWBOLD, Evan, PAPAPETROPOULOS, Spyridon, HIGGIN, Michelle S, LEE, Margaret S, REHLAENDER, Bruce N, DUVVURI, Muralikrishna
Format Patent
LanguageEnglish
French
German
Published 11.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.
Bibliography:Application Number: EP20190868543